The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

His roles included serving as Senior Vice President, Vaccine Research and Development, for Pfizer Inc., where he led the development of the Prevenar 13 vaccine for prevention of pneumococcal ...

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Uvax Bio, LLC, ("Uvax” or "the Company”) a privately held, clinical-stage vaccine company utilizing rational and ...

He also served as Vice President and Global Manager at Pfizer Vaccines where he led the global commercialization effort for Prevnar 13®. The Board will conduct a search for its next CEO over the ...

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...